These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 17049973

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC, Parsons SJ.
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [Abstract] [Full Text] [Related]

  • 3. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
    Dietrich CS, Greenberg VL, DeSimone CP, Modesitt SC, van Nagell JR, Craven R, Zimmer SG.
    Gynecol Oncol; 2010 Jan; 116(1):126-30. PubMed ID: 19875160
    [Abstract] [Full Text] [Related]

  • 4. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, Beck JF.
    BMC Cancer; 2006 Jul 11; 6():183. PubMed ID: 16834771
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP.
    Clin Cancer Res; 2006 Sep 15; 12(18):5570-7. PubMed ID: 17000694
    [Abstract] [Full Text] [Related]

  • 6. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.
    Cancer Chemother Pharmacol; 2010 Nov 15; 66(6):1131-40. PubMed ID: 20838997
    [Abstract] [Full Text] [Related]

  • 7. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM.
    Cancer Res; 2000 Sep 15; 60(18):5165-70. PubMed ID: 11016644
    [Abstract] [Full Text] [Related]

  • 8. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
    Angelucci A, Mari M, Millimaggi D, Giusti I, Carta G, Bologna M, Dolo V.
    Gynecol Oncol; 2010 Dec 15; 119(3):557-63. PubMed ID: 20825984
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 15; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN, Conney AH.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [Abstract] [Full Text] [Related]

  • 15. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D.
    Int J Oncol; 2007 Sep 01; 31(3):633-41. PubMed ID: 17671692
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL, Van Quill KR, O'Brien JM.
    Clin Cancer Res; 2008 May 15; 14(10):3113-23. PubMed ID: 18483379
    [Abstract] [Full Text] [Related]

  • 17. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.
    Clin Cancer Res; 2007 Dec 01; 13(23):7191-8. PubMed ID: 18056200
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status.
    Chobanian NH, Greenberg VL, Gass JM, Desimone CP, Van Nagell JR, Zimmer SG.
    Anticancer Res; 2004 Dec 01; 24(2B):539-45. PubMed ID: 15160991
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
    Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H.
    Cancer Chemother Pharmacol; 2009 Nov 01; 64(6):1115-22. PubMed ID: 19280190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.